

**RECORDATI: PUBLIC DISCLOSURE**

Milan, 1<sup>st</sup> August 2022 – Following the press release issued on date 28<sup>th</sup> July 2022, please be informed that the **Interim financial statements at 30<sup>th</sup> June 2022**, approved by the Board of Directors on 28<sup>th</sup> July 2022 and the **Independent Auditors’ Report on the interim condensed consolidated financial statements at 30<sup>th</sup> June 2022** are available to the public, as of today, at the Company’s registered office, on the Company’s website ([www.recordati.com](http://www.recordati.com)) and on the “1INFO” storage mechanism ([www.1info.it](http://www.1info.it)).

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was € 1,580.1 million, operating income was € 490.2 million and net income was € 386.0 million.*

For further information:

Recordati website: [www.recordati.it](http://www.recordati.it)

**Investor Relations**

Federica De Medici  
(39) 02 48787146

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

**Investor Relations**

Lucia Abbatantuoni  
(39) 02 48787213

e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

**Media Relations**

Brunswick: Barbara Scalchi / Andrea Mormandi  
(39) 02 9288 6200

e-mail: [recordati@brunswickgroup.com](mailto:recordati@brunswickgroup.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

## Registered Office

Via Matteo Civitali, 1  
20148 Milano, Italy  
Ph. (39) 02 487871  
Fax (39) 02 40073747  
[www.recordati.com](http://www.recordati.com)

Share Capital € 26.140.644,50 fully paid-up  
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150  
Tax Code/VAT No. 00748210150  
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l